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Differences of sex development (DSDs; also known as 
disorders of sex development) comprise a large group of 
congenital conditions of the urogenital tract and repro-
ductive system, affecting human sex determination and/or 
differentiation. Nomenclature remains controversial; 
current medical classification is largely based on the 
genetic status of the patient1 (Fig. 1). Our knowledge 
of DSDs has greatly evolved in the past decade owing 
to cutting- edge research on mammalian sex develop-
ment and the genetic mechanisms underlying DSDs2–4. 
In parallel to this research, several clinical outcome stud-
ies have been conducted; however, the results of these 
studies are inconclusive owing to small and heteroge-
neous samples, variable methodology and the inclusion 
of older, sometimes outdated, treatments and surgical 
techniques. The lack of conclusive outcome data for 
patients with DSDs has triggered large- scale collabo-
rative research that initially focused on basic science 
projects (such as the EuroDSD project) and since 2012 
began addressing clinically oriented issues and outcomes 
(for example, dsd- LIFE). These clinically oriented 
studies have provided new insight on historical trends5, 
comorbidities6 and outcomes of specific conditions7. 
The development of international registries, such as the 
I- DSD Registry, the I- CAH Registry and the DSD 
Translational Research Network8,9, was crucial in the 
development of collaborative research projects. Now that 
the registries are established, however, emerging chal-
lenges include establishing ways for patients to access 
their personal data and developing methods for the 
optimal securement of privacy.
Recommendations from 2014, 2015 and 2016 address 
diagnostic strategies and provide guidance for a holistic 
clinical approach, mostly during childhood and ado-
lescence1,10,11. Holistic approaches to treatment require 
multidisciplinary care by teams of relevant subspecialists 
working in close collaboration and a strong peer support 
network. Primary subspecialties include endocrinology, 
E x p E r t  C o n s E n s u s  d o C u m E n t
Caring for individuals with a  
difference of sex development (DSD): 
a Consensus Statement
Martine Cools  1*, Anna Nordenström2, Ralitsa Robeva3, Joanne Hall4, 
Puck Westerveld5, Christa Flück6, Birgit Köhler7, Marta Berra8, Alexander Springer  9, 
Katinka Schweizer10 and Vickie Pasterski11, on behalf of the COST Action BM1303 
working group 1
Abstract | The term differences of sex development (DSDs; also known as disorders of sex 
development) refers to a heterogeneous group of congenital conditions affecting human sex 
determination and differentiation. Several reports highlighting suboptimal physical and 
psychosexual outcomes in individuals who have a DSD led to a radical revision of nomenclature 
and management a decade ago. Whereas the resulting recommendations for holistic, 
multidisciplinary care seem to have been implemented rapidly in specialized paediatric services 
around the world, adolescents often experience difficulties in finding access to expert adult care 
and gradually or abruptly cease medical follow- up. Many adults with a DSD have health- related 
questions that remain unanswered owing to a lack of evidence pertaining to the natural evolution 
of the various conditions in later life stages. This Consensus Statement, developed by a European 
multidisciplinary group of experts, including patient representatives, summarizes evidence- based 
and experience- based recommendations for lifelong care and data collection in individuals with 
a DSD across ages and highlights clinical research priorities. By doing so, we hope to contribute to 
improving understanding and management of these conditions by involved medical professionals.  
In addition, we hope to give impetus to multicentre studies that will shed light on outcomes and 
comorbidities of DSD conditions across the lifespan.
*e- mail: martine.cools@
ugent.be
https://doi.org/10.1038/ 
s41574-018-0010-8
  volume 14 | july 2018 | 415
ConSEnSUS
Statement
NATuRe RevIeWS | EnDoCRInoloGY
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
urology, gynaecology, andrology, psychology, nursing, 
social work, genetics and medical ethics. Input from 
support and service user groups has been paramount 
in defining new research questions. As a result, clini-
cal studies focusing on comorbidities, treatment effects, 
outcomes in adults and psychosocial issues are placed 
high on the research agenda. How patients experience 
having a DSD and how they cope with medical proce-
dures need to receive more attention in research and 
clinical practice12.
Indeed, insufficient, or inadequate, medical care 
might result in adverse patient outcomes that, in 
turn, could impede participation in studies aimed at 
further improving clinical care. For example, health- 
care systems that are unable to provide longitudinal 
holistic care, with coordinated transition to adult 
services, or that proceed with treatments with poor 
knowledge of the condition (for example, owing to 
lack of subspecialties) can cause mistrust and/or a lack 
of engagement with health- care professionals among 
adults with a DSD. Other factors that might result in 
adverse patient outcomes include non- acceptance of 
the chronic condition or avoidance of medical care due 
to negative experiences of medical procedures during 
childhood13,14. The rarity and complexity of the vari-
ous conditions in combination with decentralization 
or lost follow- up of patients make studies including 
meaningful numbers of adults living with a DSD 
challenging. The resulting dearth of evidence- based 
guidelines for this cohort is then compounded further 
by demotivation of patients and caregivers to invest in 
sustainable health measures.
To address the aforementioned difficulties, we need 
to ensure that clinicians who do not have regular expo-
sure to patients with a DSD have detailed guidance in 
clinical review and data collection for patients at various 
life stages. Ensuring this would increase the potential for 
meaningful results from clinical research and decrease 
the potential for bias in clinical assessments, thus facil-
itating longitudinal, multicentre studies as the founda-
tion for evidence- based management and exchange of 
consistently formatted data in research networks such 
as I- DSD15. Finally, adherence to evidence- based proto-
cols can serve as a quality indicator for defining centres 
of expertise. Many features and management issues are 
shared by the different DSDs. Most of the areas that are 
extensively discussed here mainly pertain to the 46,XY 
DSD, 46,XX DSD and 45,X/46,XY DSD groups (Fig. 1). 
Turner syndrome and Klinefelter syndrome, which 
are grouped under the wider DSD umbrella, require a 
similar multidisciplinary approach. For these condi-
tions, however, clinical guidelines already exist and are 
widely used; therefore, they will not be addressed in this 
Consensus Statement16–18.
Standardizing the longitudinal assessment of indi-
viduals with a DSD across centres might also provide 
evidence for or against controversial procedures — such 
as surgical management of genitalia with an atypical 
appearance19–21 — and clinicians could then make deci-
sions on the basis of careful consideration of relevant 
parameters. Parameters clinicians need to consider 
when deciding on the appropriate treatment strategy 
include body appearance, psychosocial support, soci-
ocultural influences, gender- related development and 
genetic and/or biochemical background in addition to 
ethical, legal and human rights implications1. Intersex 
activists have encouraged legislative bodies worldwide 
to ban elective, irreversible genital surgery without the 
individual’s informed consent, and in some countries, 
such as Germany, legislative recommendations in this 
direction have been instituted22. In the absence of long- 
term outcome data that support or disfavour deferring 
genital surgery, there is currently little evidence that 
surgical practice has dramatically changed in recent 
years20,23. However, there is a broad consensus that 
alternatives to surgery, such as supporting families in 
parenting children who have a genital difference and/or 
facilitating psychological adjustment, have not been 
fully developed or supported by governmental health- 
care systems. Furthermore, there is a belief that stake-
holders, most notably patient groups, have not been 
sufficiently consulted in this matter24,25. Finding ways to 
raise resilient children with atypical- appearing genitalia, 
defining the precise role of (early) genital surgery in the 
management of DSDs and collecting data on psycho-
social adjustment and outcomes in both children who 
have undergone surgery and those who have not are 
considered top priorities.
From a patient perspective, structured and continued 
follow- up might increase beneficial interactions with 
health- care professionals, potentially enhancing under-
standing of the specific conditions, knowledge of future 
medical needs and compliance with the treatment26. A 
predefined schedule would greatly support patients and 
health- care staff during the vulnerable transition phase 
from adolescence to adulthood, encourage patients to 
prepare for discussions with caregivers and facilitate 
movement from one clinic to another by providing a 
personal summary of medical history27–29.
In this Consensus Statement, we aim to address the 
above outlined weaknesses in patient- centred care and 
research by reviewing existing evidence and, where this 
is absent, providing recommendations for holistic care 
and data collection in individuals with a DSD across 
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ages. Definitions of several key terms used in this article 
are provided in Box 1.
methods
This Consensus Statement was created within the 
framework of the European Cooperation in Science 
and Technology (COST) Action ‘DSDnet’, representing 
23 European Union member states, 3 near- neighbouring 
countries and 5 international partner countries. The rec-
ommendations were developed following work around 
the theme ‘standardization of clinical assessment of indi-
viduals who have a DSD’ by a focus group of clinicians 
from relevant disciplines and patient representatives. 
Data were identified by searches of the PubMed and 
Embase databases and reference lists from relevant 
papers; only original research papers and reviews later 
than 2000 and published in English were considered. All 
data were subject to extensive group discussions, taking 
place at face- to-face meetings, until consensus on actual 
status summary and recommended actions was reached. 
The resulting document was posted on a members- 
only area of the DSDnet website in August 2017 for a 
vetting process by all stakeholders, including clinicians, 
scientists, ethicists, advocates and patient and parent 
representatives. General approval of the final Consensus 
Document was reached in September 2017.
46,XY DSD
Disorders of gonadal 
development
• Complete or partial 
gonadal dysgenesis, 
monogenic forms 
(for example, SRY, 
NR5A1 and WT1)
• Testes regression
• Ovotesticular DSD
• Syndromic forms
Disorders of androgen synthesis
• Associated solely with androgen 
biosynthesis defects (mutations or 
deficiencies in HSD17B3 and 
SRD5A2, for example)
• Associated with congenital adrenal 
hyperplasia and early androgen 
biosynthesis defects (mutations 
and/or deficiencies in STAR, 
CYP11A1, HSD3B2, POR 
and CYP17A1)
• Associated with placental 
insufficiency or endocrine 
disruption 
• Syndromic forms (for example, 
Smith–Lemli–Opitz)
Disorders of androgen 
action
Complete and partial 
androgen insensitivity
Persistent Müllerian 
duct syndrome
Due to mutations or 
deficiencies in AMH 
and AMHR2
Unclassified disorders
• Hypospadias of unknown 
origin
• Epispadias
• Complex syndromic 
disorders
46,XX DSD
Disorders of gonadal 
development
• (Ovo)testicular DSD
• Monogenic forms of 
primary ovarian 
insufficiency (mutations 
in genes involved in 
gonadal (ovarian) 
development; for 
example NR5A1 
and WT1)
• Syndromic forms
Disorders of androgen excess
• Aromatase (CYP19A1) deficiency
• Congenital adrenal hyperplasia 
(mutations and/or deficiencies in 
CYP21A2, HSD3B2, CYP11B1 
and POR
• Luteoma
• Iatrogenic
Unclassified disorders
• MRKH type I and II syndrome
• Complex syndromic disorders
45,X 
Turner syndrome and variants
Sex chromosomal DSD
47,XXY 
Klinefelter syndrome and variants
45,X/46,XY and 46,XX/46,XY
• Mixed gonadal dysgenesis
• Chimerism
Primary cause Secondary root Tertiary root
Fig. 1 | Classification of DSDs. Disorders of sex development (DSDs) are classified into three main groups on the basis of the karyotype of the affected 
individual (primary cause). Each main group encompasses several subgroups (secondary root) that orient towards a specific diagnosis (tertiary root). 
MRKH, Mayer–Rokitansky–Küster–Hauser syndrome.
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Individualized care plan
Informed consent
Before undertaking any diagnostic and/or therapeu-
tic procedure, patients, or parents and/or guardians of 
minors, need to be thoroughly informed by the clinical 
team and give consent. For sensitive and/or irreversible 
procedures, such as genital surgery, we advise that the 
intervention be postponed until the individual is old 
enough to be actively involved in the decision whenever 
possible. Informed patient and/or parental consent is also 
a prerequisite to collect data and biomaterials for research 
purposes; examples of such informed consent documents 
in multiple languages can be found in the I-DSD Registry. 
A discrepancy is often perceived between research top-
ics proposed by scientists and what individuals who have 
a DSD consider important. In addition, many patients 
have felt abused in past research projects or mistreated 
by health professionals12,30. In response to these problems, 
collaborative networks, such as the DSDnet and ‘dsd- 
LIFE’ consortia, have been formed between research-
ers, health professionals, patient families and support 
groups. The dsd- LIFE study identified the research needs 
that patients and parents consider a priority (Box 2). In 
addition, in the newly established European Reference 
Network (ERN) covering rare endocrine conditions 
(Endo- ERN), patient participation in research and data-
base management is considered crucial. Collaborations 
between patients, parents, health- care professionals and 
researchers are based on trust and confidentiality 
and must be handled with utmost care.
Diagnostic investigations
All individuals with a suspected DSD need a thorough 
diagnostic evaluation, including an extensive whole- 
body and genital physical exam, biochemical and 
genetic investigations and imaging studies, with results 
discussed in the multidisciplinary team10. The ultimate 
goal is to obtain a diagnosis at the molecular genetics 
level to allow prognostic predictions and genetic coun-
selling and to set up an individualized management 
plan. Although the advent of genome- wide sequencing 
technologies has improved diagnostics, this goal cannot 
be achieved in ~50% of individuals with a 46,XY DSD, 
which highlights the importance of hitherto uniden-
tified regulatory mechanisms11,31,32. Opportunities for 
advanced genetic work- up are currently mostly availa-
ble through collaborative research projects that recruit 
patients enrolled in registries and networks; hence, 
participation of health- care providers in such networks 
is of direct benefit for patients. Biochemical work- up is 
equally important as it can, even in the absence of a 
genetic diagnosis, inform underlying pathology and 
hormonal treatments. Currently, chromatographic, 
mass spectrometric methods are recommended for 
exact steroid hormone measurements. However, these 
methods are not yet widely available, and standardiza-
tion between laboratories has only just started33. As the 
diagnostic quest can be long and hard to bear for affected 
families, such uncertainty should not result in hesitation 
towards outlining the management plan and addressing 
pending clinical issues (for example, those regarding sex 
assignment and information sharing).
Information and psychological support
Patients and parents are often facing a complex and 
previously unknown set of circumstances when they 
first learn about a DSD diagnosis. In addition, as part of 
holistic care, after the provision of medical information 
and clinical guidance patients and families should stay 
in regular contact with the clinical team (for example, 
once every 1–2 years) even in the absence of medical 
problems or treatments. Initial emotions can be over-
whelming, and continued psychosocial support is often 
needed when families are processing the diagnosis as 
well as for further decision- making34. Such counselling 
might also provide support for communication within 
a patient’s social network and for the development of a 
personalized diagnosis- specific vocabulary, in addition 
Box 1 | Glossary of common terms
Chromatographic, mass spectrometric methods
Tandem laboratory investigative techniques that can be used to analyse biochemical, 
organic and inorganic compounds commonly found in complex samples of 
environmental and biological origin.
DSDs
Congenital conditions in which chromosomal, gonadal or anatomical sex has been 
compromised, usually owing to a genetic mutation. use of the term ‘disorder’ is 
controversial in the context of naturally occurring variations.
Gender
The psychological experience of being male, female, both or neither (typically used 
regarding social and/or cultural differences rather than biological ones).
Gender identity
The core sense of the gendered self as male, female or other.
Gender role
Behaviours, preferences and traits that differ, on average, between males and females 
in a given culture and historical period.
Genome- wide sequencing
A process used to determine the sequence of most of the DNA content (whole- genome 
sequencing) or most of the protein- encoding exons found in the genome (whole- exome 
sequencing) of an individual.
Genotype
The genetic make- up of an individual organism.
Holistic health care
A system of comprehensive patient care that considers the physical, emotional, social, 
economic and spiritual needs of the patient. Holistic care in DSDs also considers the 
needs of family members of patients.
Intersex
The term that was used prior to the 2006 Consensus Statement and that has been 
replaced by DSDs, mainly in the medical literature. Some individuals have 
re-appropriated the term and identify themselves as ‘intersex’, whether or not a DSD 
has been diagnosed.
Phenotype
The set of observable characteristics of an individual resulting from the interaction of its 
genotype with the environment.
Sex
The state of being male or female (typically used regarding biological differences that 
include sex chromosomes, gonads and internal and/or external reproductive 
structures).
Sexual orientation
The direction of sexual attractions to males, females, both or neither.
DSDs, differences of sex development (also known as disorders of sex development).
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to providing help for dealing with their feelings. 
Patient- centred support focuses on individual deter-
minants of coping, such as personal attitudes, life 
experiences, cultural and religious background and 
eventual socio- economic barriers; however, it should 
also address fears, concerns and questions that are rel-
evant for individuals and families across all DSDs (for 
example, how parents and/or guardians can inform 
their child about their DSD and how they can deal 
with negative reactions). If the families and patients 
have written information on these issues available at all 
times, it might further help them gain self- confidence 
to deal with the situation.
Tension exists with regards to the use of the terms 
‘DSD’ versus ‘intersex’. Explaining the condition as a 
natural variation and promoting a non- binary view 
on sex and gender in general might alleviate this friction 
and direct the focus of discussion towards the provision 
of optimal care. If identified, most individuals prefer to 
use the specific name for their condition rather than the 
broader DSD or intersex terms25.
Transparent and complete information is crucial for 
helping patients cope throughout their lives, and patients 
often fully understand the information only after sev-
eral appointments with health- care professionals12,26. 
Diagnostic and treatment- related information should be 
given in the context of typical sex differentiation and/or 
development for improved conceptual grasp of naturally 
occurring variations. The benefits and risks of eventual 
interventions should be discussed with the patient and 
their families as part of a joint process. Today, health- 
care providers generally agree that all children who 
have a chronic condition should be informed early. This 
agreement holds true for DSDs35 and is a continuous 
process at the child’s own pace. Explaining the condition 
in an age- appropriate language to the child and adoles-
cent facilitates acceptance and can help to reduce fear 
and stigma. Clear and consistent communication pro-
motes confidence in the medical team and enables future 
joint decision- making and therapeutic compliance36 
(Box 3; Fig. 2). In cases where parents and/or guardians 
are reluctant to share developmentally appropriate and 
important clinical details with their children, a brief 
period of delay in providing this information is some-
times inevitable. At the same time, the multidisciplinary 
team has an important task in sensitively guiding the 
parents towards enhanced acceptance of the condition 
and reducing fears they might have around the process 
of informing their child.
Fertility issues are often sensitive to communicate. 
Nevertheless, informing individuals before adoles-
cence in a timely and progressive manner is considered 
appropriate37. Although the possibility of transmitting a 
genetically determined condition can be a major con-
cern, and germ cells are absent or severely reduced in 
number in the gonadal tissue of most individuals with 
a DSD condition, some options, such as early tissue 
cryopreservation, are available for a limited number of 
patients38. Although not yet clinically available, in vitro 
maturation of immature sperm or oocytes and har-
vesting germ cells from induced pluripotent stem cells 
are promising future techniques39. Therefore, stepwise 
decision- making in relation to gonadal surgery can 
guide families through this difficult process. Possibilities 
for fertility preservation using experimental procedures, 
with their ethical and economical drawbacks, should 
be carefully balanced against germ cell cancer risk or 
unwanted hormone production and considered along-
side the promotion of other ways of having a family, such 
as adoption40.
Transition of care
Much of the literature pertaining to the medical care of 
individuals with a DSD comes from paediatric practice 
and the adult perspective is not commonly represented. 
Children often transition from specialized paediat-
ric care to general adult or primary care services with 
potential loss of confidence in provision of DSD- specific 
medical management. From there, it is sometimes dif-
ficult to find a way back to an informed clinical service, 
especially because adult specialists who have a detailed 
and in- depth training in DSDs are rare. As a result, 
many adult patients describe difficulties finding good 
endocrine care41.
Ideally, the adult specialist that a patient is being trans-
ferred to would be involved early in the transition process. 
To build a trustful relationship, an open discussion of all 
available relevant medical data, including progressive 
information on any hitherto insufficiently communi-
cated aspects of the condition, is crucial. Evolving gender 
identity and sexual orientation might also become impor-
tant themes in the transition to adulthood. Experts in the 
field have developed a DSD- specific transition checklist 
for service users and multidisciplinary teams27,42 (Fig. 2).
Multidisciplinary care in adulthood
Multidisciplinary care is equally important in adult-
hood as it is in childhood and can involve specialists 
from an even wider range of disciplines. Individuals 
with congenital adrenal hyperplasia (CAH) require life-
long glucocorticoid treatment and usually additional 
mineralocorticoid replacement43. Sex hormone replace-
ment therapy (HRT) can be given to adults with non- 
functional or partially functioning gonads to promote 
cardiovascular and bone health as well as general well- 
being. In the absence of DSD- specific guidelines, clini-
cal practice usually follows published recommendations 
that have been developed for individuals with Turner or 
Klinefelter syndrome18,44.
Fertility is markedly reduced in almost all forms of 
DSDs. In CAH, optimal hormonal control is required 
in women who seek pregnancy and in men who have 
testicular adrenal rest tumours45. Assisted reproduc-
tive techniques can offer fertility prospects to some 
Box 2 | Research priorities for patients and parents
•	Information management
•	Parental support
•	Treatment choices and effects on health
•	Comorbidities and care through the lifespan
•	Tumour risk
•	outcomes in children and adults
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individuals with a DSD. Microdissection testicular 
sperm extraction (micro- TESE) could be an option 
for some men who have no sperm in their ejaculate, 
provided that sperm is present in the testis biopsy46. In 
2015, the first live births after uterus transplantation 
in women with Mayer–Rokitansky–Küster–Hauser 
(MRKH) syndrome were reported47. In women with a 
46,XY DSD who have a uterus, successful pregnancies 
after egg donation have been described, but numbers 
are too low to allow conclusions regarding indications 
and success rates48,49. Careful and sensitive counsel-
ling about fertility chances as well as discussing val-
uable alternatives, such as adoption, are paramount. 
Management of vaginal hypoplasia is complex and 
multifaceted. Apart from a central role for the team 
psychologist, treating vaginal hypoplasia requires 
expertise with several treatment options50.
As a result of uncertainty regarding the genital aspect 
and/or function, and possibly impaired body image, 
many individuals who have a DSD fear intimacy and 
report anxiety and distress related to sexuality, resulting 
in a tendency to delay or avoid sexual experience51. The 
gynaecologist and urologist, along with the team’s sex-
ologist or psychologist, are well placed to discuss such 
issues. Psychological support and counselling can also be 
offered to adults with a DSD at one or more occasions in 
life. Topics include dealing with the disclosure of diag-
nostic results or the condition itself, attaining medical 
files and, in patients who have not been previously or 
fully informed of the DSD, learning one’s story. In psy-
chotherapy, the loss of body integrity, sexual fear and 
anger towards parents and the medical system are fre-
quent concerns52. Importantly, engaging with (online) 
support groups, individual peer support and forging 
partnerships between communities, professionals and 
voluntary groups have proved beneficial for adolescents 
and adults living with DSDs and should be encouraged 
whenever possible53.
Hurdles in practical implementation
With respect to the recommended provision of care by 
specialized multidisciplinary teams, logistical practi-
calities have meant that many individuals with a DSD 
continue to be followed by single specialists ((paediatric) 
endocrinologists, urologists or gynaecologists). 
Implementation of multidisciplinary- team-related 
guidelines requires drastic centralization and structural 
collaboration of reference centres in large networks, 
such as the recently established ERNs. The aims of such 
guidelines should prioritize the development of, and 
adherence to, standard care protocols and data collection 
while investing in sustainable registries that promote 
secure exchange and analysis of clinical data according 
to FAIR (findable, accessible, interoperable and reusable) 
principles54. Shared diagnostic strategies, research exper-
tise and biobanks within the network can overcome 
differences in health- care levels. Patient engagement, at 
the level of both individual health- care providers and 
networks, is paramount. In some centres, peer counsel-
ling is a fundamental component of care before critical 
decision- making (for example, related to genital sur-
gery). Others have, in collaboration with parents and 
representatives, developed web- based decision- support 
tools55. There are examples of support groups investing 
in the professional training of family members willing 
to provide peer support30. Indeed, from our experience, 
this training is indispensable as it enables the peer to 
provide non- judgemental support to the patients and it 
informs families in a way that encourages them to make 
their individual decisions.
Within the Endo- ERN, patients are represented at all 
levels. Patients are actively involved in network govern-
ance and development and/or the critical appraisal of 
network- related protocols and identified research pri-
orities. Although such developments have been strongly 
encouraged by the European Commission’s Action Plan 
for Rare Diseases, they await further legislative and 
financial support from governmental bodies along with 
a definitive switch to a patient- centred care paradigm. 
Further development of peer support will require major 
investments in training programmes and remuneration 
of provided time and expertise.
suggested data collection across ages
Assessment of genital status and follow- up
Impaired body experiences, such as decreased body sat-
isfaction or decreased feeling of attractiveness in adults 
with a DSD, have resulted, in part, from past negative 
experiences12. Therefore, all genital assessments should 
be limited to a minimum and performed with great 
 caution and with explicit consent from patients and 
Box 3 | Essential components of psychosocial care to affected families
Basic requirements for dealing with patients
•	Acknowledge variety, complexity and individuality
•	Create an atmosphere of appreciation and acceptance
•	Provide time, empowerment and encouragement
Information for parents
•	Biological: explain the condition as a naturally occurring variation
•	medical: explain sex and gender as non- binary concepts and in the context of sex 
determination and differentiation; provide precise information on the specific condition; 
provide information on vital, functional and elective medical interventions, including risks 
and benefits; and offer alternatives (for example, guidance on how to tackle potentially 
difficult situations and on how to raise resilient children who have a genital difference)
•	Gender- related: discriminate between childhood (play) behaviour and adult gender 
identity; explain that the initial decisions on social gender role may be subject to later 
change according to the self- expression of the developing child; and put forward 
gender contentedness as the ultimate goal
•	use sensitive and respectful language (for example, avoid using terms such as 
malformation and disorder)
•	Communication: listen, repeat information and ask for questions
•	Promote contact with support groups and participation of appropriately trained 
peers in the decision- making process or in the multidisciplinary team
Psychological counselling
•	Discuss communication within the family and social environment and support 
decision- making on (provisional) gender role, medical interventions and judicial 
options or regulations (for example, birth certificate entry)
•	Promote acceptance of individual development
•	Avoid emotionally driven decisions, delay non- urgent decisions (such as those on 
surgery) until psychological counselling has been given and promote participation  
of trained peers in the decision- making process
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parents and or/guardians. Repeated genital exams, med-
ical photography without appropriate informed consent 
and the presence of multiple health professionals dur-
ing physical examination should be strictly avoided. 
Recommendations on how to perform necessary gen-
ital exams in children who have genital differences, and 
for preparing the child for this procedure, have been 
described elsewhere56.
Genital assessment in neonates, children and adolescents. 
In male neonates and infants, description of exter-
nal genitalia is facilitated by the use of a specifically 
designed, quantitative scoring system, the external mas-
culinization score (EMS)57. A modified, non- binary ver-
sion, applicable in both boys and girls and which aims to 
be more objective than the widely used Prader score58, 
is currently being validated in a European multicentre 
study. The anogenital distance correlates with prenatal 
androgen exposure, but standardization of this meas-
urement is yet to be established59. Prepubertal girls, in 
general, do not require assessment of the vaginal status, 
especially in the absence of previous surgery. The indica-
tion and timing of such a procedure should be individu-
alized but are usually not indicated before (induction of) 
puberty. When a uterus is present, a gynaecological 
examination should determine whether anatomy allows 
trouble- free menstrual flow41. When the measurement 
of vaginal length and/or vaginal examination in a puber-
tal girl without a uterus is planned (a procedure that is 
conducted mainly for deciding whether to use vaginal 
dilation therapy and then supporting the therapy), the 
need for local or general anaesthesia should be discussed 
and agreed upon with the individual. Reference values 
for genital dimensions in adult women, but not teenage 
girls, have been published elsewhere60.
Long- term outcome of surgical procedures. Reconstructive 
surgery has always been a substantial part of DSD care 
and has remained so for many years seemingly without 
debate. However, this has changed dramatically following 
disquieting reports of unfavourable outcomes, including 
high complication and/or reoperation rates and patient 
dissatisfaction61–65. A more patient- centred approach has 
been adopted and was informed by public discussions66,67. 
Modern reconstructive surgery claims that it is possible 
to create functionally and cosmetically normal- appearing 
genitalia; however, there is still no consensus regarding 
indication, timing or procedures of choice20,68.
The lack of consensus is partially driven by a dearth of 
relevant, systematic data, which is due to the rarity 
of the conditions, the heterogeneity of presentations, 
the loss of patients from follow- up into adulthood and the 
long interval between surgery and time of data collection. 
As a consequence, many studies report on long- term 
results of surgical techniques that are no longer in use50,69. 
As legal liability of genital surgery becomes increasingly 
important, centralization of expertise and structured 
assessment, audit and meticulous documentation of out-
comes in prospective registries are paramount19,21. Such 
assessments must include documentation of complica-
tion rate, functional outcome (micturition (urination) 
and sexuality), cosmetic outcome, quality of life, psy-
chosexual functioning and, finally, re- evaluation of the 
indication. Although genital surgery can involve a radical 
approach to the urinary tract, the effects on urinary func-
tion and the pelvic floor (including safe urine storage 
and drainage, urinary continence and risk of infection) 
are often insufficiently addressed70. Validated tools are 
available for clinical assessment and self-assessment 
of masculinizing surgery outcomes, including 
HOPE, HOSE, PPS and SAGAS- M71–74. Reliable tools 
Age 4 years Age 6 years Early puberty Late pubertal age Adulthood
Information to child 
about sex, gender and 
differences has started
• Continue information 
and answer questions
• Discuss puberty
• Consider introducing 
privacy during PE
• Privacy during PE
• All information given
• Check knowledge
• Discuss transition
• Organize transition
• Joint consultation(s)
• Check knowledge 
and autonomy
• Continued updates of 
all information
• Discussion of recommended 
follow-up visits and screenings
Psychosocial and peer support
• Words and vocabulary
• Principles of body 
functioning, hormones 
and condition 
• Naturally occurring 
variations 
• Play behaviour 
• Shame, secrecy and 
guilt
• Condition-typical aspects 
of body functioning 
• Naming condition 
• Puberty (induction) 
• Fertility 
• Gendered-type behaviour 
• Bullying and isolation
• Chromosomes 
• Sexuality 
• Vaginal hypoplasia 
• Testes prostheses 
• GCC surveillance 
• Gender contentedness 
• Peers and relations
• Fertility and gamete 
preservation 
• Delayed gonadectomy
and/or clitoral surgery 
• Gender contentedness 
• Partnership and sexual 
functioning
• Overall QoL 
• Quality of sexual life 
• PS functioning 
• Fertility issues 
• Gender contentedness
Timing and topics might vary largely between individuals
Information provided to affected individual
Information provided to parents
Fig. 2 | Multidisciplinary care and data collection in DSDs across ages. 
Multidisciplinary care and data collection begins at diagnosis and continues 
across the lifespan of the individual. The focus of the information process 
gradually shifts from parents to the affected child. Psychological and peer 
support are key elements at all ages. Although timing and topics may vary 
according to individual circumstances, it is generally agreed that children 
should be informed about their condition at an early age. Suggested themes 
to be discussed by team members are shown in blue boxes at the top of the 
figure, and (non- exhaustive) lists of important topics within these themes 
are represented in pink boxes in the centre of the figure. DSDs, differences 
of sex development; GCC, germ cell cancer ; PE, physical examination; PS, 
psychosexual; QoL , quality of life.
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for assessing outcomes of feminizing surgery are 
needed as today clinicians must heavily rely on their 
personal experience75.
Germ cell cancers. The various forms of XY and X/
XY DSD have a variable risk of developing a gonadal 
germ cell cancer, which is further modulated by 
patient age, location of the gonad and, possibly, 
genetic predisposition76 (Fig. 3a). The risk is much 
higher in men and women with gonadal dysgenesis, 
especially forms that arise from early gonadal differ-
entiation defects, such as mutations in SRY and WT1, 
than in individuals with ovotesticular DSD or with 
hormone synthesis or action disorders (for example, 
androgen insensitivity syndrome)77–81 (Fig. 3b). The 
underlying pathogenic mechanisms and proposed 
management were reviewed elsewhere in 2015 and 
2017 (reFs76,82). An increasing number of adults with 
a DSD have retained gonads1. Only in the coming 
decades, and with meticulous documentation of all 
factors involved, will the effects of advancing age, 
concomitant diseases, inadequate HRT, use of other 
medications or long- term exposure to environmental 
disruptors and lifestyle habits on the development 
and prognosis of gonadal cancer become evident. 
While awaiting these new data, and in the absence 
of reliable tumour markers or imaging technologies 
for early detection of precursor lesions, it seems 
prudent to consider gonadal biopsies to exclude the 
presence of germ cell neoplasia in situ or gonadoblas-
toma in most individuals with 46,XY or 45,X/46,XY 
DSD with retained gonads. Given that the age of 
distribution for testicular germ cell cancers is well 
established, such biopsies are best performed in late 
adolescence82,83.
Somatic assessment
The developmental origin of DSD conditions and the 
effect they can have on the functioning of several organ 
systems warrant extensive somatic assessment of all 
individuals presenting with a DSD, irrespective of age 
(Fig. 4). A detailed physical examination should be aimed 
at excluding anomalies of other organ systems, such as 
heart, lungs, kidneys or the skeleton, and of syndromic 
features, such as short fourth metacarpal or metatarsal in 
individuals who have 45,X/46,XY DSD or large uplifted 
earlobes as seen in children who have Mowat- Wilson 
syndrome6,84.
The standardization of somatic assessments is cru-
cial to secure the validity of cross- centre data pooling 
with the aim of revealing hitherto unrecognized 
health consequences and outcomes. Indeed, scarce 
data suggest that adults who have a DSD experience 
more health problems than the general population85,86. 
Not surprisingly, morbidities related to deficiencies in 
or treatment with sex steroids or glucocorticoids are 
over- represented. Although most immediate effects 
of HRT, and their importance for general well- being 
and quality of life in adulthood, are well known, the 
beneficial effects of HRT on specific brain functions, 
such as cognition or emotional processing, especially in 
elderly persons, are only beginning to be understood87. 
Follow- up of long- term effects of different HRT regi-
mens into adulthood is scarce but is much needed to 
aid healthy ageing.
Birthweight. Complications at conception or in early 
pregnancy and reduced fetal growth have long been 
associated with atypical male genital development88 
and male subfertility89. Cryptorchidism occurs with 
increased frequency in preterm infants and infants 
born small for gestational age; the odds ratio for hav-
ing hypospadias when born small for gestational age is 
4.34 (reF.90). Conversely, in men with a clinical picture 
of partial androgen insensitivity syndrome (PAIS), a 
mutation in the androgen receptor is more likely if 
birthweight is within the normal range than if birth-
weight is outside the normal range91. Presently, it is 
unclear whether intrauterine growth restriction con-
tributes to the development of hypospadias or whether 
both conditions result from a common underlying 
aetiology, but androgens per se do not seem to play a 
notable role in prenatal body growth. Possibly other, 
so- far unidentified, factors regulate differentiation 
and development of the urethra as well as prenatal 
growth91,92.
Associated congenital anomalies. Some forms of DSDs 
are intrinsically associated with developmental defects 
affecting other organ systems, reflecting the impor-
tance of many DSD- related genes, mostly those that 
encode transcription factors, in extragonadal embry-
onic development. Congenital heart defects are seen 
in individuals with 46,XY DSD who have GATA4 
and FOG2 (also known as ZFPM2) mutations93,94. 
Cardiovascular pathology in men and women with 
45,X/46,XY DSD is similar to that in women with 
Turner syndrome, irrespective of the clinical pheno-
type95. Coding and structural variations in SOX9 or 
some of its regulatory regions can cause, apart from 
XX or XY DSD, a severe skeletal condition known 
as campomelic dysplasia32. Skeletal, as well as renal, 
involvement is common in MRKH syndrome96. The 
Denys–Drash, Frasier and the Wilms tumour, aniridia, 
genitourinary malformations, mental retardation 
(WAGR) syndromes, all three of which are caused 
by mutations and structural variations in WT1, are 
associated with severe kidney disorders and end- 
stage renal  failure97,98. Upper urinary tract and kidney 
abnormalities are sporadically reported in hypospa-
dias and androgen insensitivity syndrome6; however, 
the long- term outcome of these conditions with regard 
to kidney  function is largely unknown.
Mutations in SF1 (also known as NR5A1) were 
first identified in individuals with 46,XY DSD with 
combined adrenal and gonadal defects99 but have 
subsequently been observed in individuals with XX or 
XY karyotypes with a broad range of isolated gonadal 
or reproductive phenotypes. We currently do not know 
whether adrenal function can deteriorate in these per-
sons over time. Sf1 has also been implicated in murine 
spleen development, and in 2014 and 2016, asplenia 
and/or hyposplenia was reported in some individuals 
with SF1 mutations with undetermined functional 
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consequences100,101. The FOXL2 and RSPO1 genes 
are, apart from their role in ovarian development and 
maintenance, involved in developmental conditions 
affecting the eye (such as blepharophimosis, ptosis 
and epicanthus inversus syndrome) and skin (such as 
palmoplantar hyperkeratosis and a predisposition for 
squamous cell carcinoma)102,103.
Childhood and adolescent growth. Children with 
45,X/46,XY karyotypes are at high risk of adult short 
stature, similar to girls with Turner syndrome, irrespec-
tive of growth hormone therapy104,105. The contribution 
of the sex chromosomes or the postnatal gonadotropin 
surge to growth and final height is still largely unknown. 
In addition, the nature of many DSD conditions, the 
absence of sex steroids in late childhood and/or 
the timing of puberty induction can alter typical growth 
patterns106. Therefore, anthropometric data supply useful 
information in the assessment of individuals of all ages 
with a DSD.
Bone mineralization and osteoporosis. To date, there 
has not been a systematic documentation of bone 
development in children and adolescents who have a 
DSD; however, decreased BMD is a common feature 
in adults with a DSD. Important factors that determine 
outcome with regard to bone strength are a late diagno-
sis, the type and severity of hormone deficiencies, the 
duration and doses of HRT, vitamin D status, physical 
activity, concomitant diseases, other medication and/or 
medications and heredity107.
Women with 46,XX disorders of ovarian development 
or maintenance have a marked decrease in BMD of the 
lumbar spine and femoral neck108. Decreased BMD has 
also been reported in up to 70% of women with CAH 
aged 30 years or older86,109. In this condition, compro-
mised bone health is related not to the disease per se but 
to lifelong corticosteroid replacement therapy110. Only 
a handful of small- scale studies have investigated bone 
health in individuals with 46,XY DSD. Women with 
the complete form of androgen insensitivity syndrome 
(CAIS) who had gonadectomy have a notable decrease 
in BMD in comparison with male and female reference 
values, whereas BMD seems to be less compromised in 
women with CAIS who have retained testes111,112. Both the 
lack of androgenic effects at the bone level and subnormal 
oestrogen levels contribute to reduced bone health110,113. 
Partially virilized women with 46,XY gonadal dysgene-
sis have a normal BMD114. No reports on fracture risk in 
elderly individuals who have a DSD currently exist.
Obesity, diabetes, hypertension and cardiovascular dis-
eases. Individuals who have a sex chromosome DSD are 
at increased risk of autoimmune disorders (such as type 1 
diabetes mellitus and autoimmune thyroid disease), met-
abolic disturbances and type 2 diabetes mellitus115–117. 
The prevalence of these conditions in men and women 
with 46,XY DSD is poorly documented. Increased prev-
alence of obesity, insulin resistance and lipid abnormal-
ities has been reported in women with CAIS, possibly 
due to loss of androgen receptor signalling118. Although 
genetically engineered Sf1-knockout mice (Sf1−/−) have 
increased vulnerability to develop obesity119, current 
clinical data do not support an association between 
SF1 mutations and obesity in humans120.
Metabolic disturbances are expected in women with 
46,XX DSD who have a virilizing condition. Treatment- 
naive and corticosteroid- treated adult women with CAH 
have increased BMI, insulin resistance and higher blood 
levels of glucose following an oral glucose tolerance test than 
healthy controls121. High glucocorticoid doses correlate 
positively with obesity in CAH adults86,109. The prevalence 
of the metabolic syndrome is not well defined in other DSD 
groups. Of note, individuals who receive HRT might be 
vulnerable to metabolic disturbances, and clinicians should 
screen these patients accordingly. Obesity can contribute 
to the development of hypertension and cardiovascular 
diseases122. Increased blood pressure is an int rinsic feature 
of some forms of CAH, such as 11β- hydroxylase defi-
ciency, and in 17α- hydroxylase/17,20-lyase deficiency123. 
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Fig. 3 | Factors influencing germ cell cancer risk in individuals with 46,XY or 
45,X/46,XY DSD. a | Testicular germ cell cancers in the general male population  
have a peak incidence in late adolescence and early adulthood, as represented by  
the incidence projection curve (solid pink line), possibly related to the rise in androgen 
exposure from puberty onwards (pink dashed line, representing this hypothetical 
relation); this age distribution seems to be similar in individuals who have a  
difference of sex development (DSD). b | The risk of gonadal germ cell cancer in 
individuals with a 46,XY or 45,X/46,XY DSD is related to the degree of differentiation 
(or ‘testicularization’) of the gonads, which can be derived from histopathological and 
immunohistochemical characteristics, such as the overall morphological aspect, 
maturational disturbances of the germ cells, inappropriate presence of pluripotent 
germ cells and impaired Sertoli or granulosa cell differentiation. Germ cell neoplasia 
in situ is the expected precursor lesion in gonads with testicular differentiation; 
gonadoblastoma is typically observed in highly undifferentiated gonads. The risk is 
believed to be greater in abdominal than in inguinal or scrotal gonads. Genetic 
predisposition (for example, by the combined presence of testicular germ cell 
cancer-related single- nucleotide polymorphisms) can further modify the risk of gonadal 
germ cell cancer78,83. GCNIS, germ cell neoplasia in situ.
  volume 14 | july 2018 | 423NATuRe RevIeWS | EnDoCRInoloGY
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
C o n S e n S u S  S tat e m e n t
Increased blood pressure can also result from fludrocorti-
sone overtreatment124,125. Whether cardiovascular function 
is altered in other forms of DSDs is unclear, but detailed 
assessment and follow- up of the cardiovascular system 
seem important in many individuals with DSDs, especially 
those on HRT.
Central nervous system involvement. An increased 
prevalence of cognitive and motor disturbances and 
neuropsychiatric conditions has been described in 
individuals with sex chromosome aneuploidies and, 
to a lesser extent, in individuals who have other forms 
of sex chromosomal DSD126,127. The neural system 
Genetic assessment: appropriate consultations in case of hereditary gonadal disease or susceptibility prior to conception
Genetic assessment: karyotype and investigations aimed at obtaining a molecular genetic diagnosis and determining heredity
Clinical assessment
B
irth
Infancy
A
dulthood
C
hildhood 
A
dolescence 
Milestones Signs and markers Focus and/or aims Specific tools Current gaps and future 
developments
Milestones Signs and markers Focus and/or aims Specific tools Current gaps and future 
developments
External 
phenotype
• Aspects of genitalia
• Spontaneous pubertal signs
• Function and appearance
• Appropriate pubertal 
development
• EMS
• Prader scale
• Tanner staging
• FGS
• Non-binary and objective 
external genitalia scoring 
system
Internal
genitalia
• Position and size of gonads
• Development of 
Müllerian and Wolffian 
structures
• Functional capacity
• Function and appearance • Orchidometer
• US
• MRI
• Laparoscopy
• New non-invasive
tools for evaluation of
gonadal function
Urological
assessment
• History
• Bladder function
• Uroflow and urodynamics
• External genitalia appearance
• Prevention of incontinence
and urinary tract infection
• LUTS
• US
• Cystourethrogram
• MRI
• DSD-specific standardized 
tool to describe long-term 
urogynaecological outcome
• DSD-specific standardized 
tool to describe long-term 
urogyanecological outcome
Sexual
assessment
• Appearance of external 
genitalia and breasts
• Sensation
• Erectile function and QoSL
• Satisfactory sexual life in 
non-operated and 
operated patients
• DSD-specific QoSL 
questionnaires
• QoSL
• Questionnaires
Gynaecological
assessment
• History
• External and internal genitalia 
appearance and function
• Function and appearance • US
• MRI
• Laparoscopy
Growth 
and bone 
development
• Neonatal biometry and 
detailed anthropometry
• Bone maturation 
• Bone mass accrual
• Normal growth and 
development
• Growth chart
• Skeletal age
• DXA
• pQCT
• Age-specific reference 
values for bone mass
Associated 
features and 
diseases
• Gonadal cancers
• Involvement of other organs 
and systems
• Treatment of concomitant 
diseases
• X-ray
• US, CT and/or MRI
• Gonadal biopsy
• Non-invasive screening 
methods for gonadal 
cancers
Fertility
assessment
• History
• Folliculometry and sperm quality
• Hormonal markers
• Biopsy (number and 
maturation of germ cells)
• Preservation and 
enhancement of fertility
• Follow-up of the 
offspring’s health
• Sperm analysis 
and/or US
• ART
• Gamete and tissue 
cryopreservation
• Further development 
of ART
• Uterus transplantation 
• Cell reprogramming
Biochemical assessment
Milestones Gonadal function Adrenal function Pituitary function Other organ and systems function
Psychological assessment
• QoL
• Gender 
contentedness
• QoL components
• Gender dysphoria signs
• Satisfactory QoL
• (Lack of) gender 
dysphoria
• QoL and
• Gender dysphoria 
questionnaires
• Personal assessment
• Sexual assessment
• DSD-specific QoL
• Questionnaires
• Age-specific tool for 
assessment of gender
Fig. 4 | Assessment of a patient with a DSD in the clinical practice. 
Assessment of an individual with a (potential) difference of sex development 
(DSD) starts prenatally , followed by age- dependent relevant assessments 
throughout life. Holistic assessment includes genetic, clinical, biochemical and 
psychological investigations in a wide range of specific domains (left column). 
For each of these domains, defined signs and markers are available that can be 
used to screen for potential problems. The use of a pre- identified set of tools 
enables standardized assessment for each domain, focusing on relevant 
outcomes. Current gaps and future developments are listed in the right 
column. Dotted lines indicate inter-relations between the DSD patient and the 
family members and/or partners; solid lines indicate inter- relations between 
the different aspects of assessments according to the age of the DSD patient. 
ART, assisted reproductive technology ; DXA , dual- energy X- ray 
absorptiometry ; EMS, external masculinization score, FGS, Ferriman- Gallwey 
score; LUTS, lower urinary tract symptoms; pQCT, peripheral quantitative CT; 
QoL , quality of life; QoSL , quality of sexual life; US, ultrasonography.
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remains largely unexplored in non- chromosomal 
DSD. Several cases of 46,XY DSD have been associated 
with sensorimotor neuropathy, suggesting a hetero-
geneous molecular genetic basis for the neurological 
complications128. The X- linked α- thalassemia men-
tal retardation (ATRX) syndrome is associated with 
genital abnormalities ranging from cryptorchidism to 
streak gonads and female- looking external genitalia 
in up to 80% of affected individuals who have a 46,XY 
karyotype129. Mental retardation is an important feature 
of the WAGR syndrome but not the Denys–Drash or 
Frasier syndromes130.
Psychiatric morbidity, anxiety and substance abuse 
are common among both women and men with 
CAH131,132. Glucocorticoid abnormalities can be respon-
sible for reduced working memory in both girls and 
boys with CAH133, whereas prenatal exposure to excess 
androgens in females is probably related to alterations in 
aggression, activity level and gender- related interests134. 
The influence of prenatal dexamethasone treatment on 
the fetal brain, when used to avoid intrauterine viriliza-
tion of external genitalia in pregnancies at risk of CAH, 
is poorly understood. Research indicates negative effects 
on working memory, even after short- term exposure lim-
ited to the first trimester, in unaffected individuals135–137. 
Long- term outcome data are needed to address the 
controversies around this treatment.
Hormonal and genetic data
Clinical outcome is intrinsically linked to endocrine 
function and underlying genetic mechanisms. As illus-
trated in Fig. 4 and Supplementary Table 1, detailed 
hormonal data and molecular genetic investigations 
need to be meticulously collated and archived for future 
large- scale data analysis.
Assessment of psychological outcome
Psychological adjustment and psychopathology. Some 
studies report increased prevalence of psychological dis-
tress, self- harm and suicidal tendencies in individuals 
who have a DSD52. Known causes include experi-
encing taboo, shame or secrecy; however, living with 
chronic illness and DSD- related physiological sequelae 
might also contribute to increased distress35,138. Peer 
support has been shown to have positive effects on 
psychological well- being30. Factors related to medical 
care, such as hormonal status and level of informa-
tion sharing, can hinder or facilitate acceptance of the 
condition12,26. Documentation of the communication 
process will ultimately enable study of the effect of 
adequate (and inadequate) information and participa-
tion in decision- making on psychological adjustment 
and coping.
Gender contentedness. Assessment of gender iden-
tity and gender- related behaviour in individuals 
with a DSD has become a particularly sensitive topic 
given evolving sociological perspectives on a histor-
ically binary framework of sex and gender. Societal 
acceptance of non- stereotypic gender presentation 
and non- binary gender identities has increased in the 
past decade139. In a clinical setting, this has translated 
into recognition of the need for nuance in assessing 
gender- related presentation. For example, gender role 
behaviour and/or presentation should be considered 
as distinct from core gender identity, which is defined as 
the basic sense of self as male and/or female and/
or other, in drawing clinical conclusions about gen-
der development140. In the most recent version of the 
Diagnostic and Statistical Manual for Mental Disorders 
(DSM-5)141, the diagnostic criteria for gender dys-
phoria have changed to reflect this distinction. In 
contrast to past conceptualizations, in which a gen-
der non- conforming presentation could have been 
diagnosed (or misdiagnosed) as gender dysphoria, a 
strong desire to be another or other gender must now 
be clearly demonstrated by an individual. In addition, 
the new formulation includes the provision for a diag-
nosis in individuals with a DSD, in contrast to previous 
 editions where the presence of a DSD was considered 
an exclusionary criterion.
According to the literature, the above distinction 
is critical for assessing gender- related development in 
DSDs. Although variance in gender role behaviour or 
sexual orientation might draw clinical attention and/or 
warrant provision for added psychological support, dis-
tress related to core gender identity is a more serious 
matter, with the potential need for medical intervention, 
such as a revised hormone replacement regime or 
surgical gender reassignment139. Although there is a 
growing recognition of gender and gender identity as 
a continuum rather than a binary concept, the major-
ity of individuals with DSDs identify with the gender 
designated at birth, that being either male or female, as 
do >99% of the general population142. However, rates of 
gender dysphoria, intersex, intergender identities and/
or gender change are higher in patients with DSDs than 
in the general population143–151. The greater degree of 
variance in gender- related development in DSDs than 
in non- DSD populations is probably due to a com-
plex interaction of genes, varied exposure to sex hor-
mones in the perinatal period and again at puberty and 
the psychological and/or emotional sequelae of living 
with a DSD.
A holistic and patient- centred model of health care 
should be sensitive to the potential for  secondary distress 
arising from discomfort with one’s gender. Therefore, 
enquiries about an individual’s gen der experience and 
gender- related contentedness are important. At the same 
time, the assessment should be framed in a way that does 
not stigmatize or pathologize any particular gendered 
presentation. Questions can be asked in an open- ended 
manner so as not to raise a ‘typical or atypical’ dichotomy. 
In addition, the criterion of note with respect to poten-
tial clinical concern is the presence of distress. ‘Atypical’ 
presentation is very often not accompanied by distress, 
and gender- related contentedness is mostly satisfac-
tory in such cases150. The aim of these questions is to 
give patients and families support relevant to physical, 
psychological and emotional aspects of DSDs in an 
open- minded and caring environment150. A review of 
psychological assessment across the lifespan addresses 
the nuance and complexities of gender development 
in DSDs152.
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Quality of life
Optimizing quality of life is a primary goal of holistic 
care and outcome- focused research. Given the rarity 
of the individual conditions, most studies include a 
conglomerate of diagnoses, which yields inconsistent 
results and the general conclusion that DSD- related 
quality of life is understudied153,154. In addition, earlier 
studies report on women who have not experienced 
the current patient- centred standard of care by a multi-
disciplinary team. Studies on larger series of mainly 
XY DSD conditions show overall equal quality of life, 
compared with the local general population, although 
some studies suggest suboptimal quality of life, specif-
ically in the social and psychological, but not physical, 
domains154–158. In conclusion, appropriate question-
naires should be designed for assessing quality of life in 
individuals with diverse sex development, focusing on 
partnership, sexuality and fertility, in addition to those 
assessing physical quality of life.
Conclusions
Within the management of DSDs, many unsolved 
questions remain, especially in older age groups. 
The  establishment of proper genotype–phenotype 
 correlations and addressing the identified gaps in our 
current knowledge are primary tasks of future research. 
To reach these goals, it is crucial that patient follow- 
up continues throughout their lives in dedicated refer-
ence centres, where possible. Prospective multicentre 
data collection in adults is one of the most urgent needs 
given that this has been a long- neglected group with 
respect to clinical research.
According to a scarce and dispersed literature, many 
adults who have a DSD are probably at increased risk of 
various cardiovascular, metabolic and neuropsychologi-
cal comorbidities, possibly related to the specific genetic 
constitution or to current treatments. The benefits and 
risks of HRT in patients with DSDs specifically are 
largely unknown and need further studies.
Concerns exist with regards to the effects of delayed 
genital and gonadal surgery on social acceptance, psy-
chological well- being, parent–child bonding, body image 
and sexual functioning as well as the malignancy risk of 
retained gonads. Studies assessing the effect of deferred 
surgery on the above domains and comparing psycholog-
ical outcomes with and without surgery are underway. In 
addition, insight into reasons why families might some-
times insist on having genital surgery for their child and 
investment in support tools and guidance for families 
and children living with atypical genitalia are urgently 
needed. Meanwhile, an appropriate balance between gen-
ital surgery on the one hand and the protection of human 
rights and dealing with ethical dilemmas on the other 
must be found. Longitudinal studies of genital surgery 
that focus on genital outcomes, and that neglect urinary 
functioning, can lead to inappropriate conclusions.
The creation of multidisciplinary teams dedicated to 
the management of DSD conditions worldwide poses 
its own challenges. Apart from economical limitations 
and practical hurdles, training of staff with respect to 
the acquisition of knowledge, as well as communication 
skills, is an ongoing endeavour159. Examples that outline 
the role of team members as well as team responsibili-
ties are available28,160. Developing networks of peers who 
have received specific training and who can be included 
in the multidisciplinary team can enrich the decision- 
making process with a (so far) under- represented and 
much broader perspective.
Towards the aims of facilitating systematic and struc-
tured patient follow- up in parallel with accumulating 
much- needed data for future DSD research, consensus 
among health- care providers, researchers and service 
users is crucial. To avoid selection bias in patient- 
reported outcomes, we recommend a standardized, 
non- binary and holistic assessment of individuals at 
specific life stages and in the context of mandatory clin-
ical assessment or review. Prospective studies are best 
managed in a multidisciplinary setting, including both 
paediatric and adult specialists, with the aim of system-
atic, longitudinal data collection using evidence- based, 
standardized assessment tools and protocols. By doing 
so, critical developmental milestones and/or long- term 
sequelae associated with various DSD conditions can be 
captured. Rapid translation of obtained clinical research 
data into evidence- based practice requires investment 
in enhanced communication strategies, systems for 
electronic data storage, exchange and analysis, foster-
ing a long- term vision of the organization of health- 
care structures and improved professional and public 
understanding of the needs and actions that drive pro-
gress on this matter. Large- scale networks that are cur-
rently being formed, such as Endo- ERN in Europe and 
the DSD Translational Research Network in the United 
States, are promising developments in this direction. At 
the root of the endeavour, holistic health care and clini-
cal research should always be performed in accordance 
with each patient’s expectations and with sincere respect 
for their integrity.
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